635
-0.63%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About StemCell Institute
Its shares trade on Tokyo Stock Exchange under the ticker 7096.T. It has been listed since 25 June 2021. In the fiscal year to 31 March 2026, it reported revenue of ¥2.81bn and net income of ¥155.9m. At that date it held total assets of ¥8.12bn and shareholders' equity of ¥2.68bn.
StemCell Institute KK engages in stem cell banking business. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2021-06-25. The firm operates cell bank business from umbilical cord blood and umbilical cord, development of new treatment methods and regenerative medicine products, regenerative medicine and fertility treatment, business development and investment in childbirth and childcare areas. The firm operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo and Midori-ku, Yokohama. The company is stored at its cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 25 Jun 2021
- Employees
- 92
- Website
- stemcell.co.jp ↗
Leadership
Pay as last reported
- Mr. Takafumi ShimizuPresident, Representative Director, since 2016
- Ms. Kei KayanoExecutive Officer, Chief Financial Officer, Chief Director of Finance and Accounting in Administrative Unit
- Mr. Katsuhiro TaniExecutive Officer, Senior Chief Director of Human Resource and General Affairs in Administration Unit
- Mr. Mamoru IshiiExecutive Officer
- Mr. Hideaki SatoExecutive Officer
- Mr. Kakushi TsuchiyamaExecutive Officer
- Mr. Kimihide AndoIndependent Director
- Ms. Yumi OkuboIndependent Director
- Mr. Tomoo YamadaIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- StemCell Institute KK operates cell bank business from umbilical cord blood and cord in Minato-ku, Tokyo.
- The company employs 92 full-time employees for stem cell banking and regenerative medicine development.
- StemCell Institute KK stores stem cells at ultra-low temperature in Midori-ku, Yokohama, Kanagawa.
Weaknesses
- The company's cell storage center is located in Midori-ku, Yokohama, Kanagawa, which may limit accessibility for some customers.
- StemCell Institute KK's business development focuses on childbirth and childcare areas, potentially restricting market reach.
- The firm's IPO on 25 June 2021 may indicate limited financial history for investors.
Opportunities
- StemCell Institute KK can expand its regenerative medicine products in the Health Care sector.
- The company can develop new treatment methods for fertility treatments in the Health Care industry.
- StemCell Institute KK may grow its cell bank business segment by targeting more domestic hospitals.
Threats
- StemCell Institute KK faces competition from other stem cell banking services in Japan.
- The company's reliance on umbilical cord blood collection from domestic hospitals could be disrupted by hospital partnerships.
- Regenerative medicine regulations in Japan may change, affecting business operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.